Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration...
Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and...
Bristol Myers Squibb and RayzeBio, Inc., announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in...
Bristol Myers Squibb, announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from...
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for repotrectinib, a next-generation tyrosine...
